Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 17/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 11/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963475 | 0.76 | ACHE (0.48) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21962951 | 0.76 | ACHE (0.52) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22020326 | 0.74 | ACHE (0.50) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30162458 | 0.74 | ACHE (0.50) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL22019979 | 0.74 | ACHE (0.46) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30162299 | 0.74 | ACHE (0.46) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963471 | 0.73 | ACHE (0.44) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963080 | 0.71 | ACHE (0.46) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL21963238 | 0.71 | ACHE (0.42) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL24162734 | 0.69 | ACHE (0.43) | ACHEMEN1MAPK1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880660-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |